News
Media
Conference
Publications
Resources
Partners
Subscribe

Spotlight -

Geographic Atrophy

Advancement in the management of wet AMD

EP. 1: Introduction and definition of macular degeneration

November 19th 2020

A panel of experts in macular degeneration describe a typical patient with wet age-related macular degeneration (wet AMD).

EP. 2: Identifying a typical patient with Wet AMD

November 19th 2020

Aleksandra Rachitskaya, MD, and Thomas Albini, MD, discuss the data comparing clinical trials to real-world evidence and the impact on treatment of wet AMD.

EP. 3: Clinical trials vs real-world data on wet AMD

November 19th 2020

Thomas Albini, MD, and Aleksandra Rachitskaya, MD, review the anti-VEGF agents used for the treatment of wet AMD.

EP. 4: Anti-VEGF agents for treatment of wet AMD

November 19th 2020

EP. 5: Personal experience with anti-VEGF agents for wet AMD

November 19th 2020

EP. 6: Reasons for switching between agents for wet AMD

November 19th 2020

EP. 7: Safety concerns with anti-VEGF agents for wet AMD

November 19th 2020

EP. 8: Role of biosimilars in management of wet AMD

November 19th 2020

EP. 9: Compounds and home monitoring device in development for wet AMD

November 19th 2020

EP. 10: The impact of COVID-19 on the management of wet AMD

November 19th 2020

EP. 11: The use of telemedicine for wet AMD treatment

November 19th 2020

EP. 12: Final thoughts on the progression of treatment for wet AMD

November 19th 2020

Trending on Modern Retina

Evolving strategies in retinal care: Navigating today’s treatment landscape

Regeneron receives another CRL for its Eylea 8 mg

ONL Therapeutics randomly assigns first patient in phase 2 GALAXY trial evaluating xelafaslatide

Iron dysregulation may drive AMD, new study results show

© 2025 MJH Life Sciences^®

All rights reserved.